Gland Pharma's Visakhapatnam Facilities Clear USFDA Inspection With Zero Form 483 Observations
Visakhapatnam: Gland Pharma Limited has announced that its VSEZ Sterile Oncology Formulations Facility and API Facility in Visakhapatnam have successfully concluded a routine inspection by the United States Food and Drug Administration (USFDA), with zero Form 483 observations.
The USFDA conducted the routine Good Manufacturing Practice (GMP) inspection at the company’s VSEZ Sterile Oncology Formulations Facility and API Facility in Visakhapatnam from August 24, 2026, to September 1, 2026.
The inspection concluded with ZERO (0) Form 483 observations.
The filing stated that details of any violations or contraventions were not applicable. It also noted that the impact on the company’s financial, operational or other activities, quantifiable in monetary terms to the extent possible, was not applicable.
Also Read: Gland Pharma Wins USFDA Approval for Generic Bridion Injection, Launches Product in US
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.